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Introduction
Although apoptosis occurs extensively during neuronal develop-
ment, it is rarely observed and presumably no longer desired 
in the mature brain (for review see Benn and Woolf, 2004). 
However, apoptosis has been observed in adult neurons in re-
sponse to several pathological situations including neurodegener-
ative diseases and brain injury, and as a side effect of chemotherapy 
(Lazarus et al., 1981; Yuan and Yankner, 2000). How the apop-
totic pathway is restricted in mature neurons and how these re-
strictions are overcome after pathological stimuli is unclear.
Multiple cellular stressors cause activation of the cas-
pase proteases and apoptosis in neurons (Putcha and Johnson, 
2004). The intrinsic pathway of apoptosis is regulated by the 
Bcl-2 family of proteins, which control mitochondrial release 
of cytochrome c. Once in the cytosol, cytochrome c binds to 
Apaf-1 to form the apoptosome complex. Recruitment of pro-
caspase-9 to the apoptosome results in its activation, allowing 
it to cleave and activate executioner caspases, such as caspase-3, 
which orchestrate the destruction of the cell (Boatright and 
Salvesen, 2003). Using knockout mice, we have previously dem-
onstrated that Apaf-1, caspase-9, and caspase-3 are necessary for 
cytochrome c–induced apoptosis in sympathetic neurons (Wright 
et al., 2007).
Developing sympathetic neurons (postnatal day 5 [P5]) 
are acutely dependent on NGF for survival and undergo Bax-
mediated cytochrome c release and caspase activation when de-
prived of NGF (Putcha and Johnson, 2004). In contrast, mature 
sympathetic neurons (P28) fail to undergo apoptosis after NGF 
deprivation because of the inability of Bax to translocate to 
the mitochondria (Easton et al., 1997; Putcha et al., 2000; 
Orike et al., 2001). Whether other fundamental differences 
exist in the regulation of apoptosis between developing and 
mature sympathetic neurons remains unclear.
Cytochrome c–dependent apoptosis in developing sympa-
thetic neurons relies on overcoming endogenous X-linked inhibitor 
of apoptosis protein (XIAP), which inhibits active caspases. 
Cytosolic cytochrome c alone is incapable of inducing apoptosis 
in developing P5 sympathetic neurons (Deshmukh and Johnson, 
1998; Neame et al., 1998) unless XIAP is inactivated (Potts et al., 
2003). Thus, developing sympathetic neurons engage a XIAP-
mediated “safety brake” that ensures they do not undergo apop-
tosis unless required.
Here, we fi  nd that neurons acquire an additional, inhibitor 
of apoptosis protein (IAP)–independent resistance to apoptosis 
as they mature. Importantly, we identify chromatin modifi  cation 
Chromatin modiﬁ  cation of Apaf-1 restricts the 
apoptotic pathway in mature neurons
Kevin M. Wright,
1 Michelle I. Smith,
1,2 Lila Farrag,
1 and Mohanish Deshmukh
1,2
1Neuroscience Center and 
2Department of Cell and Developmental Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599
A
lthough apoptosis has been extensively studied in 
developing neurons, the dynamic changes in this 
pathway after neuronal maturation remain largely 
unexplored. We show that as neurons mature, cytochrome c–
mediated apoptosis progresses from inhibitor of apop-
tosis protein–dependent to –independent regulation be-
cause of a complete loss of Apaf-1 expression. However, 
after DNA damage, mature neurons resynthesize Apaf-1 
through the cell cycle–related E2F1 pathway and restore 
their apoptotic potential. Surprisingly, we ﬁ  nd that E2F1 
is sufﬁ  cient to induce Apaf-1 expression in developing 
but not mature neurons. Rather, Apaf-1 up-regulation 
in mature neurons requires both chromatin derepression 
and E2F1 transcriptional activity. This differential capacity 
of E2F1 to induce Apaf-1 transcription is because of the 
association of the Apaf-1 promoter with active chromatin 
in developing neurons and repressed chromatin in mature 
neurons. These data speciﬁ  cally illustrate how the apop-
totic pathway in mature neurons becomes increasingly 
restricted by a novel mechanism involving the regulation 
of chromatin structure.
K.M. Wright and M.I. Smith contributed equally to this paper.
Correspondence to M. Deshmukh: mohanish@med.unc.edu
Abbreviations used in this paper: AcH3, acetylated histone 3; ChIP, chromatin 
immunoprecipitation; HDAC, histone deacetylase; IAP, inhibitor of apoptosis 
protein; MeH3K9, histone 3 trimethylated on lysine 9; P, postnatal day; Smac, 
second mitochondria-derived activator of caspases; TSA, trichostatin A; XIAP, 
X-linked IAP.
The online version of this paper contains supplemental material.JCB • VOLUME 179 • NUMBER 5 • 2007  826
as important mechanisms by which apoptotic resistance is 
regulated in maturing neurons.
Results and discussion
Mature sympathetic neurons restrict their 
cytochrome c–dependent apoptotic pathway 
by a mechanism independent of IAPs
In developing P5 neurons, apoptosome-dependent caspase 
activation is strictly regulated by endogenous XIAP, as cyto-
chrome c is insuffi  cient to induce apoptosis in wild-type neurons 
but does so effectively in XIAP-defi  cient neurons (Fig. 1 a; 
Potts et al., 2003). Surprisingly, XIAP-defi  cient mature P28 
neurons remained completely resistant to injection of cyto-
chrome c (Fig. 1 a). This resistance was not caused by increased 
regulation by other IAPs, as coinjection of cytochrome c and 
second mitochondria-derived activator of caspases (Smac; an 
inhibitor of IAPs) was unable to induce apoptosis (Fig. 1 a). 
These results indicate that the apoptotic pathway in mature 
P28 neurons becomes further restricted by mechanisms inde-
pendent of IAPs.
To determine the underlying mechanism of resistance to 
cytochrome c in mature neurons, we compared levels of pro-
apoptotic proteins in developing P5 and mature P28 neurons. 
To obtain P5 neurons, P0 neurons were isolated and cultured for 
5 d in vitro, and P6–13 neurons were maintained in culture until 
the P28 equivalent before experimentation. Although the levels 
of caspase-9 and -3 remained relatively unchanged, the levels of 
Apaf-1, which were already low in P5 neurons (Wright et al., 
2004), decreased to nearly undetectable levels in P28 neurons 
(Fig. 1 b). A similar loss of Apaf-1 expression was seen in sym-
pathetic ganglia isolated from P28 mice (Fig. 1 b), confi  rming 
the observations in cultured neurons. These results are consis-
tent with previous papers showing a marked reduction in Apaf-1 
levels in the adult cortex (Yakovlev et al., 2001) and retina 
(Donovan and Cotter, 2002).
We tested whether restoration of Apaf-1 would sensitize 
these cells to cytochrome c. P28 neurons were injected with 
Figure 1.  Mature sympathetic neurons develop an IAP-
independent restriction of the apoptosome pathway because 
of a loss of Apaf-1 expression. (a) P5 and 28 sympathetic 
neurons were isolated from XIAP−/− mice or wild-type litter-
mates (XIAP+/+) and injected with cytochrome c or cyto-
chrome c and Smac. After injection, cell viability was assessed 
at the indicated time points. (b) Wild-type sympathetic neu-
rons were maintained in culture until the P5 or 28 equivalent 
or superior cervical ganglia were isolated from P5 and 28 
mice. Protein levels were analyzed by Western blotting. Den-
sitometry of protein levels are represented as fold change ± 
SEM and normalized to nucleoporin levels. (c) Wild-type 
P28 sympathetic neurons were injected with constructs en-
coding EGFP and either Apaf-1 or procaspase-9. After 24 h, 
expressing cells were injected with rhodamine dextran (RD) 
with or without cytochrome c and survival was assessed at the 
indicated time points. Error bars denote ± SEM.RESTRICTED APOPTOSIS IN MATURE NEURONS • WRIGHT ET AL. 827
cDNAs expressing GFP and either Apaf-1 or procaspase-9 (as a 
control), and, after 24 h, to allow for DNA expression, GFP-
expressing cells were injected with rhodamine dextran alone 
or rhodamine dextran and cytochrome c. P28 neurons (both 
wild type and XIAP defi  cient) expressing Apaf-1 became sensi-
tive to cytochrome c, indicating that restoring Apaf-1 expres-
sion alone was suffi  cient to restore apoptosome function in 
mature neurons (Figs. 1 c and S1 a, available at http://www.jcb
.org/cgi/content/full/jcb.200708086/DC1).
DNA damage restores the ability of mature 
sympathetic neurons to undergo apoptosis 
through transcriptional up-regulation of 
Apaf-1
Despite this resistance to cytochrome c, mature neurons are ca-
pable of dying in response to DNA damage (Besirli et al., 2003), 
albeit slower than developing neurons (Fig. 2 a). Etoposide-
induced apoptotic death in mature neurons was effectively blocked 
with broad spectrum caspase inhibitors Q-VD-OPH and zVAD-
fmk (Figs. 2 and S1 b). Interestingly, the time course of cyto-
chrome c release (Fig. 2, b and c) was coincident with the time 
course of death (Fig. 2 a) in both developing and mature neurons, 
indicating that apoptosis in mature neurons is slower because of 
the delayed release of cytochrome c.
Etoposide-treated P28 neurons die shortly after the time 
of cytochrome c release, indicating that they are permissive for 
caspase activation by this point. To determine the time course 
by which caspase activation became permissive, mature neurons 
were treated with etoposide for 24 or 48 h, which are time points 
before endogenous cytochrome c release (Fig. 2, b and c), and 
injected with cytochrome c. Single cell microinjection of cyto-
chrome c allows bypass of any restrictions upstream of the 
mitochondria and direct focus on assessing the ability of the 
apoptosome to induce apoptosis. Mature neurons treated with 
etoposide for 24 h remained resistant (Fig. S2, available at http://
www.jcb.org/cgi/content/full/jcb.200708086/DC1); however, 
at 48 h they underwent rapid apoptosis after injection of cyto-
chrome c (Fig. 3 a). Injecting yeast cytochrome c, which is unable 
to induce apoptosome formation, did not result in signifi  cant 
death. Notably, P28 neurons treated with etoposide in the pres-
ence of either actinomycin D to inhibit transcription or cyclo-
heximide to inhibit protein synthesis remained resistant to 
cytochrome c (Fig. 3 a). This indicates that both transcription 
and translation are required for sensitization to cytochrome c–
induced apoptosis after DNA damage in mature neurons.
We reasoned that mature P28 neurons must restore ex-
pression of Apaf-1 after treatment with etoposide. Indeed, after 
48 h of etoposide treatment, a time that precedes endogenous 
Figure 2.  Mature sympathetic neurons release cytochrome c and undergo apoptosis in response to DNA damage. (a) P5 and 28 sympathetic neurons were 
either left untreated or treated with etoposide. Where indicated, the caspase inhibitor Q-VD-OPH was added. Cell viability, indicated by intact phase-bright 
cell bodies, was assessed at the indicated time points. (b) Status of cytochrome c in etoposide-treated P5 and 28 neurons was assessed by immunohisto-
chemistry for the indicated times. Mitochondrial cytochrome c retains an intact punctate staining pattern, which disappears after release to the cytosol. 
Nuclei were stained with Hoechst 33258 and Q-VD-OPH was added to the cultures to maintain the nuclei. Bar, 15 μm. (c) Quantiﬁ  cation of P5 and 28 
sympathetic neurons with intact mitochondrial cytochrome c after etoposide treatment for the indicated times. Error bars denote ± SEM.JCB • VOLUME 179 • NUMBER 5 • 2007  828
cytochrome c release (Fig. 1, b and c), Apaf-1 was dramati-
cally increased at both the mRNA and protein level (Fig. 3 b).
Importantly, Apaf-1–defi  cient P28 neurons were unable to regain 
sensitivity to cytochrome c after 48 h of etoposide treatment 
(Fig. 3 c). These results show that mature neurons are critically 
dependent on the induction of Apaf-1 after DNA damage to 
permit cytochrome c–mediated caspase activation.
Cell cycle gene expression is necessary 
but not sufﬁ  cient for transcriptional 
up-regulation of Apaf-1 and sensitivity to 
cytochrome c in mature neurons
To determine how Apaf-1 is transcriptionally induced in mature 
neurons after etoposide treatment, we examined Apaf-1 tran-
scription factors p53 and E2F1 (Fortin et al., 2001; Moroni et al., 
2001). We narrowed our focus to the E2F1 pathway, as the 
majority of etoposide-treated p53-defi  cient mature neurons 
showed sensitivity to cytochrome c (Fig. S3, available at http://
www.jcb.org/cgi/content/full/jcb.200708086/DC1). Inhibition of 
the E2F1 pathway by multiple mechanisms has been shown to 
be suffi  cient to delay or inhibit apoptosis in developing neurons 
(Park et al., 1996; Greene et al., 2004). E2F transcription factors 
are held inactive by hypophosphorylated retinoblastoma protein 
pocket proteins, which dissociate after their phosphorylation 
by the Cdks. We used two different Cdk inhibitors, roscovitine 
and fl  avopiridol, to block etoposide-induced E2F activation 
(Padmanabhan et al., 1999). The addition of either inhibitor 
completely blocked the etoposide-induced up-regulation of 
Apaf-1 and the sensitization of mature neurons to cytochrome c 
(Fig. 4, a and b), demonstrating that the Cdk-dependent activa-
tion of the E2F pathway is necessary for the transcription of 
Apaf-1 by DNA damage in mature neurons.
Surprisingly, although expression of E2F1 alone was 
suffi  cient to induce Apaf-1 transcription in P5 neurons, it was 
unable to do so in P28 neurons (Fig. 4 c). Consistent with this 
observation, P5 neurons expressing E2F1 developed sensitivity 
to cytochrome c, whereas P28 neurons expressing E2F1 remained 
resistant regardless of the time allowed after E2F1 expression 
(Fig. 4 d). Importantly, the ability of E2F1 to induce sensitivity 
to cytochrome c in P5 neurons was specifi  c for its transcrip-
tional activity, as a DNA-binding mutant of E2F1 (E2F1 132E; 
Johnson et al., 1993) failed to do so (Fig. 4 d).
Together, these results show that E2F1 has a differential 
ability to induce Apaf-1 expression and therefore affect sensi-
tivity to cytochrome c in the P5 developing versus P28 mature 
neurons. The observation that the activation of the E2F pathway 
is necessary but not suffi  cient for Apaf-1 up-regulation in mature 
neurons suggests that additional molecular events are required.
Apaf-1 undergoes increased chromatin-
mediated repression in mature neurons
Transactivation of target genes by transcription factors is criti-
cally dependent on the accessibility of chromatin, which is 
regulated in part by histone modifi  cations. We speculated that 
changes in chromatin accessibility may underlie the differential 
ability of E2F1 to induce Apaf-1 transcription in developing but 
not mature neurons.
To test this prediction, we examined whether chromatin 
derepression with the addition of the histone deacetylase (HDAC) 
inhibitor trichostatin A (TSA) was suffi  cient to induce sensitiv-
ity to cytochrome c via the up-regulation of Apaf-1 in developing 
and mature neurons. Treatment with TSA induced a signifi  cant 
increase in Apaf-1 expression in developing P5 neurons but was 
unable to do so in mature P28 neurons (Fig. 5 a). Consistent 
with these results, P5 neurons treated with TSA underwent rapid 
Figure 3.  Transcriptional up-regulation of Apaf-1 after DNA damage 
sensitizes mature sympathetic neurons to cytochrome c. (a) P28 sympathetic 
neurons were treated with etoposide either alone or in the presence of 
0.1 μg/ml actinomycin D (ActD) or 1 μg/ml cycloheximide (CHX) for 48 h 
and injected with either bovine or yeast cytochrome c. After injection, cell via-
bility was assessed at the indicated time points. (b) P28 sympathetic neurons 
were left untreated or treated with etoposide for 48 h and mRNA levels 
were analyzed by RT-PCR analysis. PCR primers used to amplify Apaf-1 and 
GAPDH mRNA yielded bands of 170 and 196 nucleotides, respectively. 
Protein levels were analyzed by Western blot. Densitometry of protein levels 
are represented as fold change ± SEM and normalized to nucleoporin 
levels. (c) P28 sympathetic neurons isolated from Apaf-1−/− mice or wild-
type littermates (Apaf-1+/+) were treated with etoposide for 48 h and 
injected with either bovine or yeast cytochrome c. After injection, cell viabil-
ity was assessed at the indicated time points. Error bars denote ± SEM. RESTRICTED APOPTOSIS IN MATURE NEURONS • WRIGHT ET AL. 829
apoptosis after the injection of cytochrome c, whereas P28 
neurons remained resistant (Fig. 5 b).
Because neither E2F1 overexpression nor derepression 
with the addition of TSA alone was able to induce Apaf-1 up-
regulation in mature neurons (Figs. 4 c and 5 a), we hypothe-
sized that this region of chromatin may be highly repressed in 
mature neurons. Indeed, expression of E2F1 in the presence of 
TSA induced a marked transcriptional increase in Apaf-1 (Fig. 5 c) 
and rendered mature P28 neurons sensitive to cytochrome c 
(Fig. 5 d). This sensitivity of P28 neurons was dependent on the 
up-regulation of Apaf-1, as neurons isolated from Apaf-1–
defi  cient mice failed to undergo cytochrome c–induced apoptosis 
after TSA and E2F1 treatment (Fig. 5 e). These data support the 
model that neuronal maturation is accompanied by increased 
repression of Apaf-1 at the level of chromatin structure.
We tested this model directly with a chromatin immuno-
precipitation (ChIP) assay using antibodies to acetylated histone 3 
(AcH3), which is indicative of active chromatin, and histone 3 
trimethylated on lysine 9 (MeH3K9), which is indicative of 
chromatin in a repressed state (Fischle et al., 2003). The AcH3 
antibody selectively precipitated signifi  cantly more Apaf-1 pro-
moter from developing P5 ganglia than mature P28 ganglia, 
indicating that Apaf-1 is primarily associated with active chroma-
tin during development (Fig. 5 f). In contrast, the MeH3K9 
antibody precipitated the Apaf-1 promoter only from mature 
P28 ganglia, indicating that after neuronal maturation, this region 
of chromatin is actively repressed (Fig. 5 f). Together, these 
results show that Apaf-1 undergoes a dynamic change from an 
active chromatin state in developing neurons to a repressed chro-
matin state in mature neurons to effectively restrict the apop-
totic potential as neurons mature.
Although developing neurons undergo substantial apop-
tosis, restrictions in the apoptotic pathway are physiologi-
cally important for the long-term survival of mature neurons. 
Previous studies have shown that mature neurons develop apop-
totic restriction at the premitochondrial point of Bax function 
(Easton et al., 1997; Vekrellis et al., 1997; Vogelbaum et al., 1998). 
Bax and Apaf-1 represent logical points of control, as they 
represent two critical points in the apoptotic pathway with no 
functional redundancy in neurons. The engagement of these 
specifi  c restraints on the apoptotic pathway with neuronal 
maturation provides a mechanistic basis for the observed greater 
incidence of apoptotic death in neonatal versus adult models of 
brain injury (Blomgren et al., 2003). However, in response to 
some apoptotic insults such as DNA damage and traumatic 
brain injury (Yakovlev et al., 2001), mature neurons are able to 
overcome these restraints and reengage the apoptotic pathway, 
thus minimizing detrimental effects such as infl  ammation as-
sociated with nonapoptotic forms of death.
Although several studies have demonstrated the intriguing 
requirement for cell cycle activity in neuronal apoptosis (Greene 
et al., 2004; Becker and Bonni, 2005), its exact function has 
Figure 4.  Activation of the cell cycle machinery is necessary but not sufﬁ  cient for transcriptional up-regulation of Apaf-1 in mature neurons. (a) P28 sympa-
thetic neurons were untreated, treated with etoposide alone, or treated with etoposide and a CDK inhibitor, either 50 μM roscovitine (Rosc) or 1 μM ﬂ  avopiridol 
(Flav), for 48 h. mRNA levels were analyzed by RT-PCR. PCR primers used to amplify Apaf-1 and GAPDH mRNA yielded bands of 170 and 196 nucleotides, 
respectively. (b) P28 sympathetic neurons were either left untreated or treated with etoposide alone or etoposide and a CDK inhibitor, either 50 μm roscovitine 
or 1 μm ﬂ  avopiridol, for 48 h. Neurons were injected with cytochrome c and cell viability was assessed at the indicated time points. (c) P5 and 28 sympathetic 
neurons were infected with E2F1-expressing adenovirus. 36 h after infection, mRNA levels were analyzed by RT-PCR. PCR primers used to amplify Apaf-1 and 
GAPDH mRNA yielded bands of 170 and 196 nucleotides, respectively. (d) P5 and 28 sympathetic neurons overexpressing either E2F1 or DNA-binding 
mutant E2F1 132E were injected with cytochrome c and their survival was assessed at the indicated time points. Error bars denote ± SEM. JCB • VOLUME 179 • NUMBER 5 • 2007  830
been less clear. Our hypothesis is that because the expression 
of certain proapoptotic genes is regulated by cell cycle–related 
transcriptional factors, exit from cell cycle after differentiation 
results in decreased transcription of proapoptotic genes. Therefore, 
neurons undergoing apoptosis must fi  rst reactivate cell cycle 
machinery and synthesize proapoptotic proteins. Neurons can 
use the E2F1 pathway to reach their apoptotic threshold by 
inducing the expression of Bim (Biswas et al., 2005) and Bad 
(Konishi and Bonni, 2003) upstream of cytochrome c release and 
Apaf-1 downstream of cytochrome c.
The ability of the E2F pathway to induce expression of pro-
apoptotic target genes during neuronal apoptosis can occur 
through either direct transactivation or derepression (Greene et al., 
2004; Becker and Bonni, 2005). Disruption of a repressive com-
plex containing E2F4 and the retinoblastoma protein pocket 
protein p130 is suffi  cient for the up-regulation of proapoptotic 
E2F target genes in embryonic cortical neurons (Liu et al., 2005). 
Likewise, derepression with an HDAC inhibitor alone is suffi  cient 
to activate E2F1 target genes in early postnatal cerebellar granule 
neurons (Boutillier et al., 2003) and developing but not mature 
retina (Wallace et al., 2006). Here, we report that either over-
expression of E2F1 or HDAC inhibition was indeed suffi  cient 
to induce Apaf-1 transcription and sensitivity to cytochrome c 
in developing but not mature sympathetic neurons (Figs. 4 and 5).
In contrast, we found that both gene derepression and E2F1 
transactivation were required for Apaf-1 expression in mature 
neurons (Fig. 5, c and d), indicating that neuronal maturation is 
accompanied by the progressive repression of Apaf-1. This was 
confi  rmed by demonstrating that the Apaf-1 promoter was asso-
ciated with active chromatin (AcH3) in developing neurons and 
repressed chromatin (MeH3K9) in mature neurons (Fig. 5 f). 
These results identify the regulation of Apaf-1 transcription at 
the level of chromatin structure as a key component in restricting 
the apoptotic pathway during neuronal maturation.
Although changes in the chromatin state of proapoptotic 
genes adds a level of control for restricting apoptosis in mature 
neurons, defects in this mechanism could contribute to neuro-
degeneration by maintaining neuronal sensitivity to apoptosis 
Figure 5.  Mature sympathetic neurons require 
simultaneous chromatin derepression and tran-
scriptional activation for Apaf-1 up-regulation. 
(a) P5 and 28 sympathetic neurons were treated 
with 250 nM TSA for 24 h and mRNA levels 
were analyzed by RT-PCR. PCR primers used 
to amplify Apaf-1 and GAPDH mRNA yielded 
bands of 170 and 196 nucleotides, respec-
tively. (b) P5 and 28 sympathetic neurons were 
treated with 250 nM TSA for 24 h and in-
jected with cytochrome c. After injection, cell 
viability was assessed at the indicated time 
points. (c) P28 sympathetic neurons were in-
fected with E2F1 adenovirus. 12 h later, 250 nM 
TSA  was  added. 36 h after the initial E2F1 
adenovirus infection, mRNA levels were exam-
ined by RT-PCR. PCR primers used to amplify 
Apaf-1 and GAPDH mRNA yielded bands of 
170 and 196 nucleotides, respectively. (d) P28 
sympathetic neurons expressing either E2F1 or 
E2F1 132E were treated with or without 250 nM 
TSA. After 24 h, neurons were injected with 
cytochrome c or rhodamine dextran (RD), and 
cell viability was assessed at the indicated 
time points. (e) P28 sympathetic neurons from 
Apaf-1−/− mice or wild-type littermates 
(Apaf-1+/+) were infected with E2F1 adeno-
virus and treated with 250 nM TSA. After 
24 h, neurons were injected with cytochrome c 
or rhodamine dextran, and cell viability was 
  assessed at the indicated time points. (f) Chro-
matin was extracted from superior cervical gan-
glia isolated from P5 or 28 mice. Chromatin 
was immunoprecipitated with the indicated anti-
bodies or IgG control. Immunoprecipitated chro-
matin was used in a PCR reaction with primers 
designed to amplify a 570-nucleotide region of 
the Apaf-1 promoter. Error bars denote ± SEM. RESTRICTED APOPTOSIS IN MATURE NEURONS • WRIGHT ET AL. 831
during adulthood (Mattson and Magnus, 2006). The potential use 
of HDAC inhibitors for treatment of various cancers has recently 
gained prominence (Bolden et al., 2006). Our results caution that 
these compounds may have unintended consequences, sensitizing 
these otherwise resistant neurons to pathological stimuli.
Finally, other proapoptotic genes that are targets of the 
E2F1 pathway during neuronal apoptosis could also be repressed 
by a similar mechanism in mature neurons. Indeed, dynamic 
changes in chromatin-mediated repression of proapoptotic genes 
with maturation may represent a general mechanism designed 
to ensure the long-term survival of not only neurons but other 
postmitotic cells as well.
Materials and methods
Reagents
All reagents were obtained from Sigma-Aldrich or Thermo Fisher Scientiﬁ  c 
unless stated otherwise. Collagenase and trypsin were obtained from 
Worthington Biochemical Corporation. Q-VD-OPH was obtained from MP 
Biomedicals. Flavopiridol was a gift of D. Park (University of Ottawa, Ottawa, 
Canada). Plasmid DNAs expressing E2F1 wild type and mutant 132E 
were a gift of A. Bonni (Harvard University, Cambridge, MA). Our method 
of generating Smac protein has been described previously (Potts et al., 
2003). p53-deﬁ  cient mice were purchased from the Jackson Laboratory. 
XIAP-deﬁ  cient mice were a gift of C. Thompson (University of Pennsylvania, 
Philadelphia, PA). Apaf-1–deﬁ  cient mice were generated by J. Herz (The 
University of Texas Southwestern Medical Center, Dallas, TX) and provided 
by S. Ackerman (The Jackson Laboratory, Bar Harbor, MA).
Cell culture
Primary sympathetic neurons were isolated from superior cervical ganglia 
as described previously (Potts et al., 2003), with some modiﬁ  cations. For ma-
ture neurons, superior cervical ganglia were dissected from P6–13 mice and 
treated with 1 mg/ml collagenase followed by 1 mg/ml trypsin for 1 h 
each at 37°C. P0 neurons were maintained in culture for 5 d (for P5 neurons) 
and P6–13 neurons were maintained in culture until the P28 equivalent 
before experimentation.
Cell treatments
Where indicated, cells were treated with 20 μM etoposide. The broad spec-
trum caspase inhibitor Q-VD-OPH was used at a concentration of 25 μM. 
Cell survival was assessed at multiple time points by morphology, with cells 
that had intact, phase-bright cell bodies scored as alive. This method of as-
sessing neuronal survival correlates well with other cell survival assays such 
as trypan blue exclusion and staining with calcien AM (Potts et al., 2003). 
E2F1 and GFP adenoviruses were provided by J. Cook (University of North 
Carolina at Chapel Hill, Chapel Hill, NC). Virus particles were puriﬁ  ed on a 
cesium chloride gradient and tittered in 293T cells. P5 sympathetic neurons 
were infected at an MOI of 100–250 and P28 sympathetic neurons were 
infected at an MOI of 1,000. Data shown are mean ± SEM of three indepen-
dent experiments with a minimum of 100 cells counted for each condition.
Microinjections
Microinjections were performed as described previously (Wright et al., 
2007). DNA microinjections contained 50 ng/μl EGFP (Clontech Labora-
tories, Inc.) and 200 ng/μl of indicated plasmid. Cytochrome c injections 
were 10 mg/ml and Smac injections were 1 mg/ml. Data shown are mean ± 
SEM of at least three independent experiments and each experiment 
represents a minimum of 50 cells for each condition.
Western blot
Western blots were performed as described previously (Potts et al., 2003). 
Primary antibodies were as follows: anti-Apaf-1 (13F11; Qbiogene); anti–
procaspase-3 (9665; Cell Signaling Technology); anti–caspase-9 (M0543; 
MBL International); and anti-nucleoporin (BD Biosciences). HRP-conjugated 
secondary antibodies were purchased from Thermo Fisher Scientiﬁ   c. 
Proteins were detected using ECL-Plus and scanned with an imager (Typhoon; 
both from GE Healthcare). Data shown are representative of three inde-
pendent experiments. Densitometry was preformed using ImageJ software 
and normalized to nucleoporin levels. The densitometry is represented as 
fold change ± SEM.
Immunohistochemistry
Immunohistochemistry was performed as described previously (Wright et al., 
2007). Data shown are representative of three independent experiments. 
Status of cytochrome c with etoposide treated was preformed in the presence 
of Q-VD-OPH to block caspase activation, which allows us to block cell 
death and therefore access the status of cytochrome c (released or intact).
Semiquantitative RT-PCR
Our method for semiquantitative RT-PCR analysis has been described previ-
ously (Potts et al., 2003). Data shown are representative of three indepen-
dent experiments. Primer sets used for PCR ampliﬁ  cation of Apaf-1 and 
GAPDH were as follows: Apaf-1 forward (5′-G  A  G  G  C  A  C  A  A  T  G  G  A  T  G  C  A  A-
A  G  G  -3′) and reverse (5′-G  G  C  T  G  C  T  C  G  T  T  G  A  T  A  T  T  G  A  G  T  G  G  -3′) and GAPDH 
forward (5′-C  C  A  T  G  G  A  G  A  A  G  G  C  T  G  G  G  G  -3′) and reverse (5′-C  A  A  A  G  T  T  G  T  C  -
A  T  G  G  A  T  G  A  C  C  -3′).
ChIP assay
ChIP was performed using the Chromatin Immunoprecipitation Assay kit 
(Millipore) according to the manufacturer’s instructions. In brief, superior cer-
vical ganglia were isolated from P5 or 28 mice and washed in ice-cold PBS. 
Ganglia were cross-linked by incubating with 0.1% formaldehyde in PBS for 
30 min at room temperature. Cross-linking was halted with the addition of 
glycine to 0.125 M for 10 min. Ganglia were washed three times in ice-cold 
PBS and resuspended in 300 μl of SDS lysis buffer and tumbled for 30 min 
at 4°C. Ganglia were then sonicated for 13 pulses of 5 s each at 35% ampli-
tude with a 1-min rest period between each pulse. Sonicated chromatin was 
diluted to a ﬁ  nal volume of 1,600 μl with ChIP dilution buffer and precleared 
by incubation with 35 μl of protein A–agarose/salmon sperm DNA for 1 h 
at 4°C. After preclearing, 100 μl of the sample was set aside for input control 
and the remaining chromatin was divided equally between conditions. Sam-
ples were incubated with 5 μg of the indicated antibodies for 16 h at 4°C. 
Antibody–histone complexes were recovered by incubating with 35 μl of 
protein A–agarose/salmon sperm DNA for 5 h at 4°C. Beads were centri-
fuged, washed, and eluted according to the manufacturer’s instructions. 
Cross-linking was reversed with the addition of NaCl to a ﬁ  nal concentration 
of 200 mM for 4 h at 65°C and protein complexes were degraded with the 
addition of 2 μg proteinase K for 1 h at 45°C. DNA was recovered with 
phenol-chloroform extraction followed by ethanol precipitation at −20°C 
overnight and resuspended in 50 μl TE buffer. 5 μl DNA was used for each 
PCR reaction. A no-antibody condition was run as a negative control and a 
fraction of the preimmunoprecipitated chromatin was used to determine 
input. Data shown are representative of three independent experiments.
Primers used to amplify the region identiﬁ  ed as the minimal core pro-
moter for Apaf-1 (available from GenBank/EMBL/DDBJ under accession no. 
AJ970309) were as follows: forward (5′-G  T  A  G  G  C  A  C  A  C  A  G  C  T  C  T  A  A  A  T  A  G-
G  A  G  -3′) and reverse (5′-C  A  A  G  A  T  C  T  T  C  A  G  G  G  A  T  C  C  A  G  A  C  -3′).
Image acquisition and processing
All images were acquired by a digital black and white charge-coupled 
device camera (ORCA-ER; Hamamatsu) mounted on an inverted ﬂ  uores-
cence microscope (DMIRE 2; Leica). The secondary antibody used for 
immunohistochemistry was Cy3. Cy3 was detected by a ﬁ  lter set (TRITC DiL 
HQ) and the Hoechst 33258 was detected by a Hoechst ﬁ  lter set (both 
from Chroma Technology Corp.). The objective used was HC PL APO CS 
63× 1.32.0.60 oil (Leica). Samples were mounted in glycerol containing 
mounting media and imaged by oil immersion. All images were taken at 
room temperature. The image acquisition software was Metamorph 5.0 
(MDS Analytical Technologies). Images were scaled down and cropped in 
Photoshop (Adobe) to prepare the ﬁ  nal ﬁ  gures.
Online supplemental material
Fig. S1 shows the assessment of neuronal death of P28 XIAP-deﬁ  cient neu-
rons expressing exogenous Apaf-1 after cytochrome c microinjection. This ﬁ  g-
ure also shows the time course of neuronal survival of P28 neurons after 
treatment with etoposide in the presence of the general caspase inhibitor 
zVAD-fmk. Fig. S2 shows the assessment of neuronal survival of P28 neu-
rons treated with etoposide for 24 h followed by cytochrome c microinjec-
tion. Fig. S3 shows the assessment of neuronal death of P28 p53-deﬁ  cient 
neurons treated with etoposide for 48 h followed by cytochrome c micro-
injection. Online supplemental material is available at http://www.jcb
.org/cgi/content/full/jcb.200708086/DC1.
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